Chemical conjugate TMV - Peptide bivalent fusion vaccines improve cellular immunity and tumor protection

Bioconjugate Chemistry

Volumn 17, Issue 5, 2006, Pages 1330-1338

  McCormick, Alison A ^a   Corbo, Tina A ^a   Wykoff Clary, Sherri ^a   Palmer, Kenneth E ^a   Pogue, Gregory P ^a  

^a Large Scale Biology Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGY; EPITOPES; MAMMALS; ONCOLOGY; TUMORS; VACCINES; VIRUSES;

CELLULARS; CTL EPITOPE; FOREIGN ANTIGENS; IMMUNE RESPONSE; OVALBUMINS; PEPTIDE FUSION; PEPTIDE VACCINES; TOBACCO MOSAIC VIRUS; TUMOR PROTECTION; VACCINE EFFICACIES;

PEPTIDES;

GAMMA INTERFERON; INTEGRIN RECEPTOR; TOBACCO MOSAIC VIRUS PEPTIDE BIVALENT FUSION VACCINE; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; MOUSE; NONHUMAN; RECEPTOR BINDING; T LYMPHOCYTE;

TOBACCO MOSAIC VIRUS;

EID: 33749023050     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc060124m     Document Type: Article

References (69)

1. Slingluff, C. L., Jr., Engelhard, V. H., and Ferrone, S. (2006) Peptide and dendritic cell vaccines. Clin. Cancer Res. 12, 2342s-2345s.
2. Berzofsky, J. A., Oh, S., and Terabe, M. (2005) Peptide vaccines against cancer. Cancer Treat. Res. 123, 115-136.
3. Disis, M. L., Salazar, L. G., and Knutson, K. L. (2004) Peptide-based vaccines in breast cancer. Breast Dis. 20, 3-11.
4. Brinkman, J. A., Fausch, S. C., Weber, J. S., and Kast, W. M. (2004) Peptide-based vaccines for cancer immunotherapy. Expert Opin. Biol. Ther. 4, 181-198.
5. Celis, E., Sette, A., and Grey, H. M. (1995) Epitope selection and development of peptide based vaccines to treat cancer. Semin. Cancer Biol. 6, 329-336.
6. Livingston, P. O. (1992) Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens. Curr. Opin. Immunol. 4, 624-629.
7. Guermonprez, P., and Amigorena, S. (2005) Pathways for antigen cross presentation. Springer Semin. Immunopathol. 26, 257-271.
8. Ackerman, A. L., Kyritsis, C., Tampe, R., and Cresswell, P. (2003) Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl. Acad. Sci. U.S.A. 100, 12889-12894.
9. Lazoura, E., and Apostolopoulos, V. (2005) Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr. Med. Chem. 12, 629-639.
10. Rosenberg, S. A., Sherry, R. M., Morton, K. E., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U. S., Restifo, N. P., Hughes, M. S., Schwarz, S. L., Ngo, L. T., Mavroukakis, S. A., and White, D. E. (2006) Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J. Immunother. 29, 224-231.
11. Perambakam, S., Hallmeyer, S., Reddy, S., Mahmud, N., Bressler, L., Dechristopher, P., Mahmud, D., Nunez, R., Sosman, J. A., and Peace, D. J. (2005) Induction of specific T cell immunity in patients with prostate cancer by vaccination with psa146-154 peptide. Cancer Immunol. Immunother. 1-10.
12. Yajima, N., Yamanaka, R., Mine, T., Tsuchiya, N., Homma, J., Sano, M., Kuramoto, T., Obata, Y., Komatsu, N., Arima, Y., Yamada, A., Shigemori, M., Itoh, K., and Tanaka, R. (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. 11, 5900-5911.
13. Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., Schwartzentruber, D., Berman, D. M., Schwarz, S. L., Ngo, L. T., Mavroukakis, S. A., White, D. E., and Steinberg, S. M. (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175, 6169-6176.
14. Knutson, K. L., and Disis, M. L. (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54, 721-728.
15. Mocellin, S., Rossi, C. R., Nitti, D., Lise, M., and Marincola, F. M. (2003) Dissecting tumor responsiveness to immunotherapy. The experience of peptide-based melanoma vaccines. Biochim. Biophys. Acta 653, 61-71.
16. Fuessel, S., Meye, A., Schmitz, M., Zastrow, S., Linne, C., Richter, K., Lobel, B., Hakenberg, O. W., Hoelig, K., Rieber, E. P., and Wirth, M. P. (2006) Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial. Prostate 66, 811-821.
17. Gajewski, T. F. (2006) Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res. 12, 2326s-2330s.
18. Chattopadhyay, S., Mehrotra, S., Chhabra, A., Hegde, U., Mukherji, B., and Chakraborty, N. G. (2006) Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro. J. Immunol. 176, 984-990.
19. Antony, P. A., Piccirillo, C. A., Akpinarli, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C. C., Klebanoff, C. A., Overwijk, W. W., Rosenberg, S. A., and Restifo, N. P. (2005) Cd8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601.
20. Mayr, U. B., Walcher, P., Azimpour, C., Riedmann, E., Haller, C., and Lubitz, W. (2005) Bacterial ghosts as antigen delivery vehicles. Adv. Drug Deliv. Rev. 57, 1381-1391.
21. Yoshimura, K., Jain, A., Allen, H. E., Laird, L. S., Chia, C. Y., Ravi, S., Brockstedt, D. G., Giedlin, M. A., Bahjat, K. S., Leong, M. L., Slansky, J. E., Cook, D. N., Dubensky, T. W., Pardoll, D. M., and Schulick, R. D. (2006) Selective targeting of antitumor immune responses with engineered live-attenuated listeria monocytogenes. Cancer Res. 66, 1096-1104.
22. Franzusoff, A., Duke, R. C., King, T. H., Lu, Y., and Rodell, T. C. (2005) Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin. Biol. Ther. 5, 565-575.
23. Gathuru, J. K., Koide, F., Ragupathi, G., Adams, J. L., Kerns, R. T., Coleman, T. P., and Livingston, P. O. (2005) Identification of dhbcag as a potent carrier protein comparable to KLH for augmenting muc1 antigenicity. Vaccine 23, 4727-4733.
24. Boisgerault, F., Moron, G., and Leclerc, C. (2002) Virus-like particles: A new family of delivery systems. Expert Rev. Vaccines 1, 101-109.
25. Chackerian, B., Lenz, P., Lowy, D. R., and Schiller, J. T. (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. 169, 6120-6126.
26. Storni, T., Lechner, F., Erdmann, I., Bachi, T., Jegerlehner, A., Dumrese, T., Kundig, T. M., Ruedl, C., and Bachmann, M. F. (2002) Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol. 168, 2880-2886.
27. Pattenden, L. K., Middelberg, A. P., Niebert, M., and Lipin, D. I. (2005) Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 23, 523-529.
28. Banchereau, J., Ueno, H., Dhodapkar, M., Connolly, J., Finholt, J. P., Klechevsky, E., Blanck, J. P., Johnston, D. A., Palucka, A. K., and Fay, J. (2005) Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J. Immunother. 28, 505-516.
29. Liao, C. W., Chen, C. A., Lee, C. N., Su, Y. N., Chang, M. C., Syu, M. H., Hsieh, C. Y., and Cheng, W. F. (2005) Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res. 65, 9089-9098.
30. Kreitman, R. J. (2004) Confirmation and prevention of targeted toxicity by a recombinant fusion toxin. Mol. Cancer Ther. 3, 1691-1692.
31. Eriksson, K., Fredriksson, M., Nordstrom, I., and Holmgren, J. (2003) Cholera toxin and its β subunit promote dendritic cell vaccination with different influences on th1 and th2 development. Infect. Immun. 71, 1740-1747.
32. Ahlers, J. D., Belyakov, I. M., and Berzofsky, J. A. (2003) Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr. Mol. Med. 3, 285-301.
33. Steinaa, L., Rasmussen, P. B., Wegener, A. M., Sonderbye, L., Leach, D. R., Rygaard, J., Mouritsen, S., and Gautam, A. M. (2005) Linked foreign T-cell help activates self-reactive ctl and inhibits tumor growth. J. Immunol. 175, 329-334.
34. Dell, K., Koesters, R., and Gissmann, L. (2006) Transcutaneous immunization in mice: Induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int. J. Cancer 118, 364-372.
35. Lu, J., Higashimoto, Y., Appella, E., and Celis, E. (2004) Multiepitope trojan antigen peptide vaccines for the induction of antitumor ctl and th immune responses. J. Immunol. 172, 4575-4582.
36. Yano, A., Onozuka, A., Asahi-Ozaki, Y., Imai, S., Hanada, N., Miwa, Y., and Nisizawa, T. (2005) An ingenious design for peptide vaccines. Vaccine 23, 2322-2326.
37. Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A., Sirard, J. C., Rothlisberger, P., and Bachmann, M. F. (2003) Role of toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. 33, 1465-1470.
38. Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., and Flavell, R. A. (2004) Recognition of single-stranded RNA viruses by toll-like receptor 7. Proc. Natl. Acad. Sci. U.S.A. 101, 5598-5603.
39. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., and Reis e Sousa, C. (2004) Innate antiviral responses by means of tlr7-mediated recognition of single-stranded RNA. Science 303, 1529-1531.
40. McCormick, A. A., Corbo, T. A., Wykoff-Clary, S., Nguyen, L. V., Smith, M. L., Palmer, K. E., and Pogue, G. P. (2006) Vaccine, in press, Jul 5; Epub ahead of print.
41. Smith, M. L., Lindbo, J. A., Dillard-Telm, S., Brosio, P. M., Lasnik, A. B., McCormick, A. A., Nguyen, L. V., and Palmer, K. E. (2006) Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 348, 475-488.
42. Palmer, K. E., Benko, A., Doucette, S. A., Cameron, T. I., Foster, T., Hanley, K. M., McCormick, A. A., McCulloch, M., Pogue, G. P., Smith, M. L., and Christensen, N. D. (2006) Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing 12 capsid epitopes. Vaccine 24, 5516-5525.
43. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E., and Krieg, A. M. (1997) Immunostimulatory oligodeoxynucleotides containing the cpg motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U.S.A. 94, 10833-10837.
44. Overwijk, W. W., Surman, D. R., Tsung, K., and Restifo, N. P. (1997) Identification of a kb-restricted ctl epitope of β-galactosidase: Potential use in development of immunization protocols for "self" antigens. Methods 12, 117-123.
45. Moore, M. W., Carbone, F. R., and Bevan, M. J. (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54, 777-785.
46. Briles, E. B., and Kornfeld, S. (1978) Isolation and metastatic properties of detachment variants of b16 melanoma cells. J. Natl. Cancer Inst. 60, 1217-1222.
47. Tindle, R. W., Fernando, G. J., Sterling, J. C., and Frazer, I. H. (1991) A "public" T-helper epitope of the e7 transforming protein of human papillomavirus 16 provides cognate help for several e7 b-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. U.S.A. 88, 5887-5891.
48. Zwaveling, S., Ferreira Mota, S. C., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., and Melief, C. J. (2002) Established human papillomavirus type 16-expressing rumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358.
49. Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G., and Lanzavecchia, A. (1989) Universally immunogenic T cell epitopes: Promiscuous binding to human mhc class II and promiscuous recognition by T cells. Eur. J. Immunol. 19, 2237-2242.
50. Men, Y., Gander, B., Merkle, H. P., and Corradin, G. (1996) Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14, 1442-1450.
51. Lund, L. H., Andersson, K., Zuber, B., Karlsson, A., Engstrom, G., Hinkula, J., Wahren, B., and Winberg, G. (2003) Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (cea) plasmid DNA vaccine in a murine test system. Cancer Gene Ther. 10, 365-376.
52. Dickerson, E. B., Akhtar, N., Steinberg, H., Wang, Z. Y., Lindstrom, M. J., Padilla, M. L., Auerbach, R., and Helfand, S. C. (2004) Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the Cytokine++ to αvβ3 integrin. Mol. Cancer Res. 2, 663-673.
53. Schraa, A. J., Kok, R. J., Botter, S. M., Withoff, S., Meijer, D. K., de Leij, L. F., and Molema, G. (2004) Rgd-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward αvβ3-expressing endothelial cells. Int. J. Cancer 112, 279-285.
54. Okada, N., Iiyama, S., Okada, Y., Mizuguchi, H., Hayakawa, T., Nakagawa, S., Mayumi, T., Fujita, T., and Yamamoto, A. (2005) Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Ther. 12, 72-83.
55. Liu, Y., Ye, T., Sun, D., Maynard, J., and Deisseroth, A. (2004) Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum. Gene Ther. 15, 637-647.
56. Zeh, H. J., III, Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A., and Yang, J. C. (1999) High avidity ctls for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 989-994.
57. Tagawa, S. T., Cheung, E., Banta, W., Gee, C., and Weber, J. S. (2006) Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 106, 1353-1357.
58. Roberts, J. D., Niedzwiecki, D., Carson, W. E., Chapman, P. B., Gajewski, T. F., Ernstoff, M. S., Hodi, F. S., Shea, C., Leong, S. P., Johnson, J., Zhang, D., Houghton, A., and Haluska, F. G. (2006) Phase 2 study of the g209-2m melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and leukemia group b 509901. J. Immunother. 29, 95-101.
59. Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F., Tabilio, A., Amabile, M., Forconi, F., Gozzetti, A., Raspadori, D., Amadori, S., and Lauria, F. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet 365, 657-662.
60. Noguchi, M., Itoh, K., Yao, A., Mine, T., Yamada, A., Obata, Y., Furuta, M., Harada, M., Suekane, S., and Matsuoka, K. (2005) Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for hla-a24+ hrpc patients. Prostate 63, 1-12.
61. Uemura, H., Fujimoto, K., Tanaka, M., Yoshikawa, M., Hirao, Y., Uejima, S., Yoshikawa, K., and Itoh, K. (2006) A phase I trial of vaccination of ca9-derived peptides for hla-a24-positive patients with Cytokine-refractory metastatic renal cell carcinoma. Clin. Cancer Res. 12, 1768-1775.
62. Peoples, G. E., Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., Shriver, C. D., Ioannides, C. G., and Ponniah, S. (2005) Clinical trial results of a her2/neu (e75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. 23, 7536-7545.
63. Weihrauch, M. R., Ansen, S., Jurkiewicz, E., Geisen, C., Xia, Z., Anderson, K. S., Gracien, E., Schmidt, M., Wittig, B., Diehl, V., Wolf, J., Bohlen, H., and Nadler, L. M. (2005) Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived hla-a2-restricted cap-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res. 11, 5993-6001.
64. Carbone, D. P., Ciernik, I. F., Kelley, M. J., Smith, M. C., Nadaf, S., Kavanaugh, D., Maher, V. E., Stipanov, M., Contois, D., Johnson, B. E., Pendleton, C. D., Seifert, B., Carter, C., Read, E. J., Greenblatt, J., Top, L. E., Kelsey, M. I., Minna, J. D., and Berzofsky, J. A. (2005) Immunization with mutant p53- and k-ras-derived peptides in cancer patients: Immune response and clinical outcome. J. Clin. Oncol. 23, 5099-5107.
65. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., and Engleman, E. G. (2001) Altered peptide ligand vaccination with fltS ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 98, 8809-8814.
66. Bourdette, D. N., Edmonds, E., Smith, C., Bowen, J. D., Guttmann, C. R., Nagy, Z. P., Simon, J., Whitham, R., Lovera, J., Yadav, V., Mass, M., Spencer, L., Culbertson, N., Bartholomew, R. M., Theofan, G., Milano, J., Offner, H., and Vandenbark, A. A. (2005) A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult. Scler. 11, 552-561.
67. Audran, R., Cachat, M., Lurati, F., Soe, S., Leroy, O., Corradin, G., Druilhe, P., and Spertini, F. (2005) Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73, 8017-8026.
68. Valmori, D., Dutoit, V., Ayyoub, M., Rimoldi, D., Guillaume, P., Lienard, D., Lejeune, F., Cerottini, J. C., Romero, P., and Speiser, D. E. (2003) Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 3, 15.
69. Slingluff, C. L., Jr., Petroni, G. R., Yamshchikov, G. V., Hibbitts, S., Grosh, W. W., Chianese-Bullock, K. A., Bissonette, E. A., Barnd, D. L., Deacon, D. H., Patterson, J. W., Parekh, J., Neese, P. Y., Woodson, E. M., Wiernasz, C. J., and Merrill, P. (2004) Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22, 4474-4485.